Propanc Health Group Corp (OTCMKTS:PPCH) started the week on a weak note as the stock price declined more than 15% to close at $0.0147. The stock made a new base after the recent explosion when a newsletter termed as the Wealthy Biotech Trader said that the biotech firm is close to get novel Proenzyme Drug that can prevent and treat certain forms of cancer. The pumps like this result in short term gains followed by scary drops.

The scope

Propanc Health is working on new cancer therapies that can treat colorectal and pancreatic forms of cancer. The company developed a rational and composite formulation of ‘anti-cancer’ compounds that reflects a number of attributes to prevent or control cancer tumors from spreading throughout the body. The development work is carried out by the team of scientific and oncology consultants.

The products

Propanc drug candidates are variations upon company’s unique formulation and employ or involve pro-enzymes. As the company recorded positive early indications of its technology, it plans to submit pro-enzyme treatment to the formal clinical and non-clinical development and trial methods required to get the regulatory approval.

The objective

Propanc intends to target those patients who have limited therapeutic alternatives for the treatment of tumors including colorectal and pancreatic tumors. It intends to develop the lead products to cure early stage cancer and deadly pre-cancerous diseases. It wants to develop a preventative measure for patients who are at risk of getting cancer tumors based on genetic screening.

The future ahead

Propanc Health Group Corp (OTCMKTS:PPCH) is a working on a revolutionary new drug treatment which in initial trial stages. The aim of drug is to provide a treatment option to patients suffering from cancer. The company has been working with oncology and clinical experts, including Dr. Julian Kenyon and Professor Klaus Kutz whose combined experience of over 60 years has been critical in the R&D of PRP anti-cancer treatment.